Marcel A Mueller
Charité
7 Papers
4 Citations
Marcel A Mueller is an academic researcher from Charité. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
Markus Hoffmann,Hannah Kleine-Weber,Nadine Krueger,Marcel A Mueller,Christian Drosten,Stefan Poehlmann +5 more
TL;DR: The results reveal important commonalities between 2019-nCoV and SARS-coronavirus infection, which might translate into similar transmissibility and disease pathogenesis and identify a target for antiviral intervention.
Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster
Roman Woelfel,Victor M. Corman,Wolfgang Guggemos,M Seilmaier,Sabine Zange,Marcel A Mueller,Daniela Niemeyer,Patrick Vollmar,Camilla Rothe,Michael Hoelscher,Tobias Bleicker,Bruenink S,Julia Schneider,Rosina Ehmann,Katrin Zwirglmaier,Christian Drosten,Clemens M. Wendtner +16 more
TL;DR: It is shown that COVID-19 can often present as a common cold-like illness, and SARS-CoV-2 can actively replicate in the upper respiratory tract, and is shed for a prolonged time after symptoms end, including in stool.
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
Mario Karolyi,Erich Pawelka,Sara Omid,F. Koenig,V. Kauer,Benedikt Rumpf,Wolfgang Hoepler,Ayla Kuran,Hermann Laferl,Tamara Seitz,Marianna Traugott,Vincent Rathkolb,Marcel A Mueller,A. Abrahamowicz,Christian Schoergenhofer,Manfred Hecking,Alice Assinger,Christoph Wenisch,Markus Zeitlinger,Bernd Jilma,Alexander Zoufaly +20 more
TL;DR: In patients hospitalized for COVID-19, the use of CM was associated with shorter time to clinical improvement, reduced need for MV or death, and shorter LOS than the use with lopinavir/ritonavir or LPV/RTV.
A Sars-Cov-2 Neutralizing Antibody Protects from Lung Pathology in a Covid-19 Hamster Model
Jakob Kreye,S. Momsen Reincke,Hans-Christian Kornau,Elisa Sanchez-Sendin,Victor M. Corman,Hejun Liu,Meng Yuan,Nicholas C. Wu,Xueyong Zhu,Chang-Chun D Lee,Jakob Trimpert,Markus Hoeltje,Kristina Dietert,Laura Stoeffler,Niels von Wardenburg,Scott van Hoof,Marie A Homeyer,Julius Hoffmann,Azza Abdelgawad,Achim D. Gruber,Luca D. Bertzbach,Daria Vladimirova,Lucie Y Li,Paula Charlotte Barthel,Karl Skriner,Andreas C. Hocke,Stefan Hippenstiel,Martin Witzenrath,Norbert Suttorp,Florian Kurth,Christiana Franke,Matthias Endres,Dietmar Schmitz,Lara Maria Jeworowski,Anja Richter,Marie Luisa Schmidt,Tatjana Schwarz,Marcel A Mueller,Christian Drosten,Daniel Wendisch,Leif E. Sander,Nikolaus Osterrieder,Ian A. Wilson,Harald Pruess +43 more
TL;DR: Among 598 human monoclonal antibodies (mAbs) from ten SARS-CoV-2 patients, this article identified 40 strongly neutralizing mAbs, including CV07-209, which achieved IC 50 of 3.1 ng/ml.
A scoping review of regulatory T cell dynamics in convalescent COVID-19 patients - Implications for Long COVID?
S. Haunhorst,Wilhelm Bloch,Florian Javelle,K. Krueger,S. Baumgart,Sebastian Drube,Christina Lemhoefer,P. Reuken,Andreas Stallmach,Marcel A Mueller,Christina E. Zielinski,M. Pletz,H. Gabriel,Chilunga Puta +13 more
TL;DR: Persistent alterations in cell frequency in Long COVID patients indicate that Treg dysregulation might be linked to immune system-associated sequelae and future studies should aim to address the association of Treg adaptations with different symptom clusters and blood parameters beyond the sole quantification of cell frequencies.
1